‘Venclexta (venetoclax)’ in combination with ‘MabThera (rituximab)’ will be reimbursed as second-line treatment for patients with chronic lymphocytic leukemia.

The Health Insurance Review and Assessment Service (HIRA) has been conducting an opinion inquiry on its proposed revision of the ‘Notices required according to drugs prescribed and administered to cancer patients.’ If no objections are raised during this period, the revision will be applied and enforced from June 7th.

Venclexta was approved in combination with rituximab for ‘adult patients with chronic lymphocytic leukemia (CLL) who had at least one prior treatment.’ HIRA reviewed the reimbursement expansion based on info